Attachable Proxy Surgical Set

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company focused on improving patient outcomes and the cost and efficiency of procedures surgeries, announced today is set to join the broad Russell 3000® Index as well as the Russell 2000® and Russell Microcap® Indices at the conclusion of the annual 2022 Russell Indices Replenishment, according to a preliminary list additions published by FTSE Russell on June 3, 2022. Inclusion in the index will take effect after the US market opens on June 27, 2022.

The annual Russell Indexes replenishment captures the 4,000 largest US stocks as of May 6, ranking them by total market capitalization. Membership in the Russell 3000® All Cap US Index, which remains in place for one year, means automatic inclusion in the Russell 1000® Large Cap Index or the Russell 2000® Small Cap Index as well as appropriate style index growth and value. The Russell 2000® Index is the most common benchmark for small cap companies and the Russell Microcap® Index measures the performance of the micro cap segment of the US stock market. FTSE Russell determines membership in its Russell indices primarily based on targets, market capitalization rankings and style attributes.

“We are delighted to see Vicarious Surgical added to the Russell Indices following our successful listing on the New York Stock Exchange in September 2021,” said Adam Sachs, Managing Director of Vicarious Surgical. “This replenishment sets the stage for broader awareness and engagement within the institutional investment community as we continue our mission to transform the future of surgical robotics.”

Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Around $12 trillion in assets are benchmarked against US Russell indices. Russell Indices are part of FTSE Russell, one of the world’s leading index providers.

For more information on the reconstitution of the Russell indices, go to the “Russell reconstruction” section of the FTSE+Russell+ website.

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next-generation robotics company developing disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. . The company’s new surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including

Bill Gates , Khosla Ventures by Vinod Khosla, Innovation Endeavors, AME Cloud Ventures by Jerry Yang, Sun Hung Kai & Co. Ltd and E15 VC by Philip Liang. The company is headquartered in Waltham, Massachusetts. Learn more about

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates and projections and, therefore, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact contained herein, including, without limitation, quotes from our Managing Director regarding the desirability of Vicarious Surgical, among others, are forward-looking statements that reflect the beliefs and current management expectations. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond Vicarious Surgical’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: the impact of COVID-19 on Vicarious Surgical’s business; changes in applicable laws or regulations; Vicarious Surgical’s ability to raise funds in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s products and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for Vicarious Surgical; Vicarious Surgical’s ability to identify, license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing licensing, manufacturing, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies that currently market or are engaged in developing products and services that Vicarious Surgical currently markets or develops; the size and growth potential of the markets for Vicarious Surgical’s products and services, and its ability to serve those markets, either alone or in partnership with others; pricing for Vicarious Surgical’s products and services and reimbursement for medical procedures performed using its products and services; the company’s estimates of expenses, revenues, capital requirements and additional financing requirements; the financial performance of Vicarious Surgical; and other risks and uncertainties stated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the above list of factors is not exclusive. The company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date made. Vicarious Surgical neither undertakes nor accepts any obligation or undertaking to issue updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances about which any such statement is made. based.

See the source version on

Christine E. Phillips